NervGen Pharma | May 5, 2025 10:00 am EDT

About this Video

• Video Title: NervGen Pharma | May 5, 2025 10:00 am EDT
• Channel: Hz1.618
• Speakers: Mike Kelly
• Duration: 00:21:22

Introduction

This video features a presentation by Mike Kelly of NervGen Pharma. The presentation focuses on NervGen's lead asset, MVG291, a neuroreparative therapy for spinal cord injury, and its potential to revolutionize the treatment of this condition. Kelly details the science behind the drug, its development, clinical trials, and market potential.

Key Takeaways

• MVG291, NervGen's lead asset, is a first-in-class neuroreparative therapy discovered from research at Case Western Reserve University. It's a self-penetrating peptide designed to counteract the inhibitory effects of CSPGs (chondroitin sulfate proteoglycans) on nerve regeneration.
• Pre-clinical studies show promising results, including evidence of serotonin axon resprouting and functional recovery in animal models of spinal cord injury, even after the typical plateau phase of recovery.
• A Phase 1 study in healthy volunteers showed MVG291 to be well-tolerated, with the most common adverse event being a mild injection site reaction.
• A Phase 2 clinical trial is underway, focusing on motor-incomplete spinal cord injuries (C4-C7). The primary endpoint is electrophysiological measurement (MEP amplitude), and secondary endpoints include functional assessments. The trial is designed to measure improvement in MEP amplitude and functional outcomes in the treated group versus a placebo group.
• The market for spinal cord injury treatments is substantial, representing a multi-billion dollar opportunity, with significant unmet needs and high costs to healthcare systems. NervGen has strong patent protection and is exploring further applications of MVG291 and its pipeline drug MVG300.